Skip to main content
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. — Investor Relations & Filings

Ticker · GANX ISIN · US36269B1052 US Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2022-03-25 Annual Report
Country US United States of America
Listing US GANX

About Gain Therapeutics, Inc.

https://www.gaintherapeutics.com/

Gain Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops next-generation allosteric small molecule therapies. The company utilizes its proprietary Magellan™ drug discovery platform, which combines artificial intelligence with physics-based computational models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function to treat diseases that are currently undruggable. The company's lead candidate, GT-02287, is in Phase I clinical trials for the treatment of GBA-Parkinson’s disease. Gain's therapeutic pipeline targets neurodegenerative diseases, lysosomal storage disorders, and other conditions with high unmet medical needs.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2021
2022-03-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 24, 2022, by Gain Therapeutics, Inc. It announces the issuance of a press release with financial results for the year ended December 31, 2021, and a business update. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length is 3789 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes a press release with financial results but does not contain the full financial report should be classified as a Regulatory Filing (RNS), as it does not meet the criteria for an Earnings Release (ER) or Annual Report (10-K).
2022-03-24 English
Director's Dealing 2021
Director's Dealing
2021-12-28 English
Director's Dealing 2021
Director's Dealing
2021-12-28 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the adoption of a new equity incentive plan and the granting of stock options and restricted stock units to a new executive. This relates to changes in compensatory arrangements and appointments of officers. The key section is Item 5.02, which deals with departure or election of directors or officers and compensatory arrangements. There is no detailed financial data or comprehensive financial report, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy solicitation or voting results announcement. The document is primarily about management changes and equity incentive plans for officers, which fits the Board/Management Information category (MANG). The document length is over 6000 characters, so it is not a brief announcement. Therefore, the best classification is MANG with high confidence.
2021-12-28 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.